Risk perception and disease knowledge in attendees of a community-based lung cancer screening programme

Impact of risk perception and disease cognition on the willingness to participate in screening for lung cancer in a high-risk population

OBJECTIVE

Risk perception and disease cognition may influence the efficiency of lung cancer screening by affecting the participation rate. There is still some uncertainty regarding the association between risk perception and disease cognition and how they affect participation in lung cancer screening. Therefore, we explored the influence of risk perception and disease cognition on the willingness to participate in screening among people at high risk of lung cancer.

METHODS

Subjects with high-risk factors for lung cancer were recruited in Lu'an City, Anhui Province, China. Questionnaires were used to determine their demographic characteristics, risk perception, disease cognition, and willingness to engage in screening.

RESULTS

Of the 1955 subjects with high risk factors for lung cancer, 1136 (58.12%) were willing to participate in lung cancer screening. Univariable and multivariable analyses showed that disease cognition ( adj OR = 2.012, 95% CI: 1.528-2.649, P  = 0.000), cognitive risk ( adj OR = 7.661, 95% CI: 6.049-9.704, P  = 0.000), and affective risk ( adj OR = 5.964, 95% CI: 4.552-7.815, P  = 0.000) were significant factors in promoting screening participation. For those with moderate risk perception, improving disease cognition was a key approach to increase screening participation.

CONCLUSION

This study elucidated the relationship between various factors and lung cancer screening participation and proposed a feasible route for the screening implementation, providing a theoretical basis to further improve the participation rate and efficiency of lung cancer screening.

Study on Effects of Cyclophosphamide Combined with Vinorelbine in Advanced Small Cell Lung Cancer and Anteroposterior Changes in MRI

Objective. To explore the effects of cyclophosphamide combined with vinorelbine in advanced small cell lung cancer (SCLC) and anteroposterior changes in MRI. Methods. The clinical data of 90 patients with advanced SCLC admitted to our hospital from April 2020 to April 2021 were retrospectively analyzed. They were divided into the control group and the study group according to the order of admission, with 45 cases in each group. The control group received the routine treatment, while the study group was treated with cyclophosphamide and vinorelbine to compare the indexes of imaging data and clinical indicators between the two groups before and after treatment. Results. There was no significant difference in the indexes of imaging data between the two groups before treatment $\left(P>0.05\right)$ , and the indexes of imaging data in the study group were visibly lower than those in the control group after treatment $\left(P<0.001\right)$ . The DCR in the study group was significantly higher than that in the control group after treatment $\left(P<0.05\right)$ , while the QLQ-C30 scores and serum indices of the study group after treatment were significantly lower than those of the control group $\left(P<0.001\right)$ . Conclusion. Patients with advanced SCLC were treated with cyclophosphamide and vinorelbine, which can effectively improve the quality of life and reduce the expression of inflammatory factors. This treatment model has a higher application value, and the treatment value is also reflected compared with the routine treatment. At the same time, the permeability parameters obtained by MRI can predict the therapeutic effects of cyclophosphamide and vinorelbine, and further studies are helpful to establish a better solution for patients.